Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for isolated growth hormone deficiency type IA — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for isolated growth hormone deficiency type ia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
DNA primase subunit 1 (PRIM1) — PRIM1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 4RR2 · 2.65 Å · ligand IRON/SULFUR CLUSTER (SF4). Experimental structure, not a prediction.
A 1993 report describes the first known association of isolated growth hormone deficiency (IGHD) with combined immunodeficiency in children. The authors state that IGHD should be considered as a cause of short stature in such children before attributing growth retardation to infection. No sample size, survival data, or response rates are given in this single-case description.
A 2006 review discusses the possibility of using growth hormone therapy in conditions not strictly related to growth hormone deficiency, including chronic paediatric patients. The review does not present original data on efficacy or outcomes for IGHD type IA specifically. It notes that linear growth is only one of many expected effects of growth hormone, but provides no concrete numbers for any patient group.
A 2011 article on diagnosis and treatment of growth hormone deficiency in children states that treatment effectiveness depends on the patient's status at the time of treatment and on the dose and schedule of recombinant growth hormone. It reports a significant increase in IGF-1 and IGF-binding protein-3 during treatment compared to baseline, and suggests these markers can serve as criteria for treatment effectiveness. No survival rates, response rates, or sample sizes are provided, and the article does not distinguish IGHD type IA from other forms of deficiency.
What is still missing: no controlled trials exist for IGHD type IA specifically; no data on long-term survival or immune function outcomes; no standardised dosing or stratification by genetic subtype; and no funding for prospective studies in this rare condition.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe first description of an association of isolated growth hormone deficiency (IGHD) and combined immunodeficiency is presented. The findings suggest that IGHD should be considered as a cause of short stature in children with combined immunodeficiency before attributing growth retardation to infection.
https://doi.org/10.1136/adc.68.2.231AbstractUNLABELLED: Human growth hormone therapy is allowed in certain clinical conditions according to national healthcare criteria. Growth hormone, however, produces a wide spectrum of effects. Linear growth is only one of the many expected results, and there are interesting possibilities to explore which could provide additional means of improving the quality of life for the ever-increasing numbers of chronic paediatric patients. CONCLUSION: In this review, we discuss the rationale for and possibility of using growth hormone therapy in some conditions not strictly related to growth hormone deficiency.
https://doi.org/10.1080/08035320600649432AbstractThe article presents criteria of the diagnostics and results of treatment of children with growth hormone deficiency. Effectiveness of treatment of children with above mentioned deficiency depends on the status of the patient at the time of treatment and on the dose and schedule of administration of recombinant growth hormone. Significant increase in IGF -1 and IGF – binding protein – 3 is seen in the process of treatment with growth hormone in comparison with their background values allows us to use them not only as diagnostic criteria of growth hormone deficiency but also as criteria of effectiveness of treatment with growth hormone as well.
https://doi.org/10.24026/1818-1384.1(34).2011.86169Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
